Osimertinib, marketed as Tagrisso, faces competition from other targeted therapies and chemotherapies in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations.
What Other Drugs Treat EGFR-Mutated NSCLC?
Beyond osimertinib, other targeted therapies approved for certain EGFR mutations include first-generation tyrosine kinase inhibitors (TKIs) like gefitinib (Iressa) and erlotinib (Tarceva), as well as the second-generation TKI afatinib (Gilotrif) [1][2]. Chemotherapy regimens also remain an option, particularly for patients who may not be candidates for TKIs or for later lines of treatment [3].
How Do Osimertinib's Competitors Work?
First-generation EGFR TKIs, gefitinib and erlotinib, target common EGFR mutations such as exon 19 deletions and L858R substitutions. Afatinib, a second-generation TKI, irreversibly binds to EGFR, targeting these same mutations and also HER2 mutations [1][2]. Osimertinib is a third-generation TKI designed to be effective against common EGFR mutations and, importantly, the T790M resistance mutation that can develop after treatment with earlier-generation TKIs [4].
When Does Osimertinib's Patent Protection End?
The patent landscape for blockbuster drugs like osimertinib is complex and can involve multiple patents covering different aspects, such as the compound itself, its synthesis, and its use. Patent expiry dates are crucial for determining when generic or biosimilar versions can enter the market. Information on specific patent statuses and expected expiry dates for osimertinib can be found on platforms like DrugPatentWatch.com [5].
What Are the Risks of Using Alternative Treatments?
While alternative treatments can be effective, they may present different risk profiles. For example, early-generation TKIs might have higher rates of certain side effects or lower efficacy against specific resistance mutations compared to osimertinib [4]. Chemotherapy, while broadly applicable, often carries a different set of toxicities, including myelosuppression and gastrointestinal issues [3].
How Does Osimertinib Compare to Other Treatments?
Clinical trials have shown osimertinib to be highly effective in patients with EGFR-mutated NSCLC, particularly those with the T790M mutation, demonstrating improved progression-free survival and overall survival compared to older TKIs in first-line settings [4]. Comparisons with chemotherapy often highlight the superior tolerability and efficacy of targeted therapies in appropriately selected patient populations.
Who Are the Key Manufacturers in This Space?
AstraZeneca manufactures osimertinib (Tagrisso) [4]. Other companies involved in the development and marketing of competing EGFR inhibitors include AstraZeneca for gefitinib (Iressa), Genentech/Roche for erlotinib (Tarceva), and Boehringer Ingelheim for afatinib (Gilotrif) [1][2]. The development of generic versions after patent expiry involves numerous pharmaceutical manufacturers globally.
Can Biosimilars Enter Before Patent Expiry?
Biosimilars are generally only able to enter the market after the expiry of relevant patents and any associated exclusivity periods for the originator biologic drug. While osimertinib is a small molecule drug, and the term "generic" is more commonly used for these, the principle of market exclusivity driven by patents applies [5]. The development and approval process for generics is distinct from that of biosimilars, which apply to biologic medicines.
What Are the Latest Developments in NSCLC Treatment?
Research continues to explore new treatment strategies for NSCLC, including novel combinations of TKIs with other agents, antibody-drug conjugates, and immunotherapies. The understanding of tumor resistance mechanisms is also evolving, leading to the development of next-generation targeted therapies designed to overcome these challenges [4].
Sources:
[1] https://drugpatentwatch.com/en/drug/gefitinib
[2] https://drugpatentwatch.com/en/drug/afatinib
[3] https://www.cancer.org/cancer/types/lung-cancer/treating.html
[4] DrugPatentWatch.com
[5] https://drugpatentwatch.com/